Despite a recent Phase 2 failure, the LARC2 kinase target for Parkinson's is gaining renewed interest. The strategy is to move beyond "all-comer" trials to focus on patients with specific genetic variants or similar genetic profiles identified through SNPs, expanding the potential patient pool from less than 5% to around 30%.
The FDA's "Operation Trial Blazer" reforms will cut US trial launch times in half, to 15 months, but this is still seven months slower than China. The US approach focuses on making sequential processes more efficient, whereas China's model runs regulatory, ethics, and preclinical work in parallel—a higher-risk but faster strategy.
The FDA is systematically unwinding regulatory setbacks from former Commissioner McCary's tenure. At least 11 products that received complete response letters or other negative feedback are now back on a more conventional path. This "reversion to the mean" is rebuilding confidence for investors and companies, particularly in rare disease.
Leading candidates for the next FDA Commissioner role lack the deep regulatory backgrounds of their predecessors. This implies that individuals appointed as permanent directors of the CBER and CEDAR drug centers will wield significant influence, as the new Commissioner will likely need to defer to their expertise on key decisions.
Regenerative cell therapies are emerging as a disease-modifying option for Parkinson's. Unlike previous attempts with fetal cells, new therapies use homogenous cell populations. This allows for precise control over the differentiation stage, enhancing safety and the potential for durable efficacy by replacing lost neurons.
AstraZeneca is assembling a multi-faceted obesity pipeline to address different patient needs, not to create one dominant drug. This includes an oral GLP-1, dual agonists for high weight loss, and an activin inhibitor for elderly patients at risk of muscle loss. This segmentation strategy aims to capture specific market slices.
The FDA is creating a network of "Qualified Research Institutions" (QRIs) to pre-review IND components. This echoes Australia's model of using third parties but with a key difference: the FDA retains final approval authority, unlike in Australia where ethics committees can independently approve low-risk trials.